New hope for babies with birth asphyxia: drug trial aims to prevent lifelong disability
NCT ID NCT01732146
Summary
This study tested whether adding a high dose of the drug erythropoietin to standard cooling therapy could improve outcomes for full-term newborns who suffered a lack of oxygen at birth (birth asphyxia). The goal was to see if the drug helped more babies survive without long-term brain problems like cerebral palsy or developmental delays. Researchers followed 120 newborns for two years to measure survival, brain development, and safety.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPOXIC ISCHEMIC ENCEPHALOPATHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cochin Hospital
Paris, 75014, France
Conditions
Explore the condition pages connected to this study.